Active (Patient Specific) Immunotherapy of Colon Cancer: A Transition from Preclinical Studies to Successful Clinical Trials

Michael G. Hanna Jr^*

Chairman and Chief Executive Officer, Vaccinogen, Inc., USA

^*Corresponding Author: Michael G. Hanna Jr, Chairman and Chief Executive Officer, Vaccinogen, Inc., USA, Tel: 301-793-7736 Email:

Introduction